A human embryonic stem cell (hESC)-based product currently being developed as a treatment for spinal cord injury is also to be investigated as a potential treatment for Alzheimer's disease.
The collaboration, jointly funded by Geron and a University of California Discovery Research and Training Grant, will investigate the therapeutic potential of Geron's product Grnopc1 in models of Alzheimer's disease.
"We are exploring a number of potential applications for Grnopc1 in neurological disease in addition to spinal cord injury," said Jane S Lebkowski, Geron's senior vice-president and chief scientific officer of regenerative medicine.
She went on to say that there are "striking parallels" between research results on mouse stem cells in Alzheimer's disease models and what is known about Grnopc1.
Meanwhile, a new wheelchair that is controlled by the user's tongue has been developed and is being tested in the US by spinal cord injury patients.
One of the patients described the wheelchair to CNN as being "amazing technology".
News brought to you by Serious Law specialists in spinal injury